drugset / Trial / NCT01311076
TAK-329 Glucose Clamp Study
RandomizedCrossoverQuadruple-blind
Summary
The purpose of this study is to compare the safety, tolerability, pharmacokinetic and pharmacodynamic properties of single doses of TAK-329 with a single dose of a subcutaneously-injected rapid-acting insulin analog in participants with type 1 diabetes mellitus.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-12
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Insulin | Protein / enzyme biologic | 0.2 iu/kg | Subcutaneous |
| Subject | TAK-329 | Unknown | 50 mg | Oral |
| Subject | TAK-329 | Unknown | 200 mg | Oral |